Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Endometrial Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Description of Evidence

continued...

Factors Associated With Increased Risk

Endogenous estrogen

Reproductive factors resulting in increased duration of exposure to endogenous estrogen, such as early menarche, nulliparity, and late menopause, are associated with an increased risk of endometrial cancer. Other factors associated with increased risk, such as obesity and polycystic ovary syndrome, may also be related to increased estrogen exposure.

The first prospective investigation of endogenous estrogens and the risk of endometrial cancer was a case-control study nested within the New York University Women's Health Study.[32] Results suggest an increased risk of endometrial cancer associated with postmenopausal levels of endogenous hormones including estradiol, percent-free estradiol, and estrone. Conversely, risk was decreased with higher levels of percent sex hormone-binding globulin (SHBG)-bound estradiol and SHBG. Analyses conducted prior to adjustment for hormone levels indicated a positive association with body mass index (BMI). After adjustment for estrone level, the positive association of BMI with risk of endometrial cancer was attenuated, suggesting that hormone levels may be an intermediate effect of body weight.[33]

Exogenous estrogen

Postmenopausal hormone therapy (HT)

An association between estrogen replacement therapy and endometrial cancer was reported in 1975 [34] and confirmed soon after.[35,36] In these three studies, the overall risk ratio ranged from 4.5 to 8.0. Further studies documented an association with duration of use (10-fold to 30-fold with 5 years or more of use),[37,38,39,40] and a persistent effect lasting more than 10 years after 1 year's use.[41] When these findings were publicized, prescriptions for estrogen declined sharply, followed rapidly by a drop in endometrial cancer incidence.[42]

Combination estrogen-progestin replacement therapy

Postmenopausal estrogen was long recognized to be associated with the risk of adenomatous hyperplasia, often a precursor of endometrial cancer.[43] In addition, progestational agents were known to be effective in the treatment of uterine neoplasms.[44,45,46] Consequently, improved postmenopausal HT was proposed, combining estrogen and progestin, so as to avoid the endometrial cancer risk associated with unopposed estrogen.[47,48]

The Postmenopausal Estrogen Progestin Interventions Trial [49] enrolled nearly 600 participants in a 3-year multicenter, double-blind, placebo-controlled trial. Five arms consisted of placebo, daily conjugated equine estrogen (CEE), CEE with progestin (medroxyprogesterone acetate [MPA] for 12 days of a 28-day cycle), CEE with micronized progesterone (MP) for 12 days of a 28-day cycle, or CEE with daily MP. Endometrial biopsies were obtained at baseline, annually, and as clinically indicated. Women on CEE had more pathologic abnormalities than women on placebo (simple hyperplasia: 27.7% vs. 0.8%, adenomatous hyperplasia: 22.7% vs. 0.8%, and atypical hyperplasia: 11.8% vs. 0%, respectively), but women on CEE with progestin did not.

A prospective cohort study was conducted among Swedish women for whom HTs were prescribed. For women using medium-potency unopposed estrogens for 6 years or more, the RR of invasive endometrial cancer was 4.2 (95% CI, 2.5–8.4) while the risk for women using a progestin-combined treatment for the same length of time was unaffected (RR = 1.4; 95% CI, 0.6–3.3).[50]

1|2|3|4|5

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article